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Conditioned medium of cultured Sertoli cells from 21-day-old rats was used as starting material for the 
isolation of inhibin. Inhibin activity was monitored by the dose dependent suppression of the follicle- 
stimulating hormone release of cultured rat pituitary cells. Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis analysis of the highly purified inhibin preparation revealed a 32 kDa protein after silver 
staining, which could be separated in subunits of 18 kDa and 12 kDa after reduction. Western blot 
analysis with an antibody recognizing the 22 N-terminal amino acids of the a-subunit of 32 kDa bovine 
inhibin confirmed the presence of a 32 kDa inhibin molecule under non-reducing conditions, whereas an 
18 kDa cY-subunit was found after reduction. An antibody recognizing the /3-A subunit of inhibin did not 
yield a signal after Western blotting. N-terminal amino acid sequence analysis of two highly purified 
preparations of inhibin obtained using different methods yielded the sequence predicted for a 32 kDa 
@-B dimer on basis of cDNA nucleotide sequence. This result is in agreement with the large excess of P-B 
over /3-A mRNA in the rat testis. 
Introduction 
Inhibin is a gonadal glyprotein hormone con- 
sisting of two dissimilar disulphide-linked sub- 
units, which inhibits pituitary gonadotrophin pro- 
duction and/or secretion, preferentially that of 
follicle stimulating hormone (FSH) (Burger and 
Igarashi, 1988). The isolation of inhibin has been 
hampered by the hydrophobic nature of the mole- 
cule, the use of different assay systems with the 
potential for detection of non-specific effects and 
the presence of different molecular weight forms 
of inhibin (de Jong, 1988). Inhibin is present in 
several gonadal fluids; the highest concentration 
of inhibin is found in ovarian follicular fluid (de 
Jong and Sharpe, 1976). Inhibin with a molecular 
mass of 32 kDa has been purified from both 
bovine (Fukuda et al., 1986; Robertson et al., 
1986) ovine (Leversha et al., 1987) and porcine 
(Ling et al., 1985; Miyamoto et al., 1985; Rivier et 
al., 1985) follicular fluid (bFF, OFF and pFF 
respectively). Upon reduction of 32 kDa inhibin 
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forms were named inhibin A and B and differed 
in the N-terminal amino acid sequences of their 
/3-subunits, which are now termed P-A and P-B. 
Subsequently, genes coding for the (Y, P-A and 
P-B-subunits have been cloned from human, 
porcine, bovine and rat cDNA libraries (for re- 
views see de Kretser and Robertson, 1989 and 
Vale et al., 1988). 
Relatively little is known about the structure of 
testicular inhibin. Bardin et al. (1987) reported the 
purification of two forms of inhibin from ovine 
rete testis fluid, both composed of an a/I-A dimer 
but one with a truncated a-subunit. Partial char- 
acterization of inhibin from Sertoli cell condi- 
tioned medium has been reported for rat (Bicsak 
et al., 1987; de Jong et al., 1987) and cynomolgus 
monkey (Noguchi et al., 1987). Here, we report 
the isolation, subunit composition and N-terminal 
amino acid sequence of a 32 kDa inhibin isolated 
from rat Sertoli cell conditioned medium. 
Materials and methods 
Bioassay for inhibin 
Inhibin-like bioactivity was determined using a 
bioassay detecting the suppression of spontaneous 
FSH release from incubated pituitary cells (Groo- 
tenhuis et al., 1989). Briefly, after a preincubation 
of pituitary cells for 3 days, media were changed 
and inhibin containing samples were added at two 
or three dose levels in triplicate. After a second 
3-day culture period the concentration of FSH in 
the incubation medium was determined. A bFF 
preparation with an arbitrary potency of 1 U/pg 
protein was used as standard. The International 
Research Standard for Inhibin (86/890, Waites et 
al., 1987) has a relative specific activity of 60 f 10 
U/pg (mean k SEM, n = 5) expressed in units of 
this bFF standard. Inhibin potencies were calcu- 
lated using statistics for assay parallelism (Finney, 
1964). 
Sertoli ceil culture 
Sertoli cells were isolated from 21-day-old 
Wistar rats using a double collagenase digestion 
method as described by Oonk et al. (1985) and 
Grootenhuis et al. (1989). Briefly, approximately 
3 X lo6 Sertoli cells (8 mg protein) were plated in 
150 cm* plastic flasks (Costar, Cambridge, MA, 
U.S.A.) in 1% fetal calf serum (FCS; Gibco, Grand 
Island, NY, U.S.A.) in minimal essential medium 
(MEM, Gibco). On the next day cells were washed 
and further cultured at 37°C in MEM, supple- 
mented with antibiotics. Rat Sertoli cell condi- 
tioned medium (rSSCM) was collected every 3 or 
4 days for 4-5 weeks and stored at - 20°C. 
Purification 
Two pools of 5 1 rSCCM were concentrated to 
a volume of 220 ml each under nitrogen pressure 
at 4°C using a filtration unit (Amicon, Lexington, 
MA, U.S.A.) using a hollowfibre (HIPlO-43; 
Amicon) with a molecular weight cut-off at 10 
kDa. The concentrate was repeatedly exchanged 
with buffer A of the Mono Q column (see below). 
Two different column sequences were used for the 
purification of inhibin, in both methods batches of 
40 ml concentrated rSCCM were applied to a 
Mono Q anion-exchange column (HR 5/5) at- 
tached to a standard FPLC system with a GP-250 
controller (Pharmacia, Uppsala, Sweden). After 
the QD2sonm P rofile reached baseline, retained 
proteins were eluted using a 30 ml linear gradient 
of O-600 mmol/l NaCl in buffer A (Tris-HCl 
buffer; 20 mmol/l, pH 9.2) at 1 ml/mm and 1 
ml/fraction. The fractions containing the peak of 
bioactivity were pooled and purified according to 
one of the methods described below. Lentil 
Lectin-Sepharose (Pharmacia) chromatography of 
hollowfibre-concentrated rSCCM was performed 
according to de Jong et al. (1987). 
Method 1. The pooled fractions, containing 
inhibin bioactivity from the Mono Q columns, 
were separated in five runs on a Cl/C8 reversed 
phase column (HR 5/20, Pharmacia) using a 30 
ml gradient of O-50% (v/v) acetonitrile containing 
0.1% (v/v) trifluoracetic acid (TFA) at 1 ml/mm 
and 1 ml/fraction (de Jong et al., 1987) using an 
FPLC system. Bioactive fractions were lyophilized 
and separated by sodium dodecyl sulphate-poly- 
acrylamide gel electrophoresis (SDS-PAGE) on 
15% gels (see below). After separation, 2 mm slices 
were cut and proteins were eluted and methanol 
precipitated as described by Grootenhuis et al. 
(1989). 
Method 2. From a second batch of rSSCM the 
bioactive fractions from the Mono Q runs were 
also pooled. One-third of this pool peak of bioac- 
tivity (an equivalent of 1200 ml rSCCM) was 
applied to a Bakerbond wide-pore Cl8 column 
(Baker Chemicals, Phillipsburg, NJ, U.S.A.) using 
a liquid chromatography system from Waters As- 
sociates (Milford, MA, U.S.A.), which consisted of 
a M-720 system controller, a M-6OOOA solvent 
delivery system, an M-441 UV/Vis absorbance 
detector, on-line equipped with a Shimadzu C-R3A 
chromatopac data module. The sample was frac- 
tionated using a 70 ml linear gradient of 20-48% 
acetonitrile in phosphate buffer (10 mmol/l; pH 
6.8) at 1 ml/mm, 1 ml/fraction and the protein 
profile was recorded at 214 nm. The bioactive 
fractions were pooled, dried by rotary evaporation 
in vacua, applied on a Cl8 aquapore RP-300 
column connected to a microbore 130A Sep- 
aration System (Applied Biosystem, Foster City, 
CA, U.S.A.) and eluted with a 50 min linear 
gradient from 18-48% acetonitrile in 0.1% TFA at 
200 ~l/min and 400 pi/fraction. Proteins in the 
eluate were detected at 210 run. 
N-terminal amino acid sequence analysis 
The amino acid sequence determination was 
performed on an Applied Biosystems model 470A 
protein sequencer, on-line equipped with a model 
120A PTH analyzer. 
SDS-PAGE 
Proteins in the fractions of the last purification 
step were separated by SDS-PAGE (Laemmli, 
1970) on gels of 15% (w/v) acrylamide and 0.8% 
(w/v) bisacrylamide, without or with prior reduc- 
tion (5 min lOO’C, 1% (v/v) /3-mercaptoethanol). 
Zsoelectrofocussing 
Isoelectrofocussing was performed on gels with 
a pH gradient of 3-9 using the Phast gel system 
(Pharmacia) according to manufacturer’s applica- 
tion notes. For calibration an isoelectrofocussing 
kit (Pharmacia) was used. 
Silver staining and Western blot analysis 
For silver staining, gels were stained with Page 
Blue 83 (Bakker et al., 1987), incubated 1 h with 
10% glutaraldehyde, washed overnight with dis- 
tilled water and stained according to the method 
of Wray et al. (1981). 
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For Western blot analysis, separated proteins 
were electroblotted onto nitrocellulose and in- 
cubated with an antiserum against the 22 N-termi- 
nal amino acids of the cr-subunit of bovine 32 kDa 
inhibin, which was described earlier by Groo- 
tenhuis et al. (1989). 
Results 
Sertoli cell conditioned medium 
Immature rat Sertoli cells cultured in medium 
without serum at 37’C produce appreciable 
amounts of bioactive inhibin (Fig. 1). After an 
initial significant rise of the inhibin concentration 
in the medium in the second week, large amounts 
of bioactive inhibin are produced up to the fifth 
week. The relative specific activity (RSA) of the 
two pools of rat Sertoli cell conditioned (rSCCM) 
medium were 20.6 and 17.1 when compared with 
the bFF standard (see Table 1). Recovery of in- 
hibin bioactivity after concentration of the pooled 
media was 121% and 95% for the first and second 
pool, respectively. 
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Fig. 1. Time-dependent production of bioactive inhibin by 
Sertoli cells, derived from 21-day-old rats cultured at 37°C. 
Media were changed twice a week for 5 weeks. Media from 1 
week were pooled and assayed together. Values are obtained 
from three different Sertoli cell preparations and are expressed 
as percentage of the value for week 1 (means* SEM; *P < 0.05 
compared with week 1, **P -c 0.05 compared with week 2 
(paired Student’s r-test)). 
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TABLE 1 
RELATIVE SPECIFIC ACTIVITY (RSA) AND RECOVERY OF INHIBIN AFTER SEVERAL STEPS DURING ITS PURIFI- 
CATION FROM RAT SERTOLI CELL CONDITIONED MEDIUM (rSCCM) 
The amount of rSCCM used in the purification with two different methods is indicated, and fractions (fr) used for the following 
purification steps are listed. Protein content was determined using: ‘Bradford, bOD,so_, or ‘amino acid analysis. 
Preparation Total RSA Recovery at Purification 
units (U/mg) each step (W) factor 
(X103) (X103) 
Method I 
rSCCM (4100 ml) 1,340 20.6 a 100 1 
> 10 kDa 1,620 34.7 = 121 1.7 
MonoQfr9+10 983 88.2 b 61 4.3 
Cl/C8 fr 5, 6, 7 189 121 b 28 5.9 
SDS-PAGE 29-32 kDa proteins 123 16,400’ 65 800 
Method 2 
rSCCM (1200 ml) 452 17.1 a 100 1 
> 10 kDa 429 21.5 a 95 1.26 
Mono Q fr 10, 11,12 174 41.3 b 40 2.5 
ClS/pH 6.8 fr 29-40 43 114b 17 6.7 
Cl8 0.1% TFA fr 18 1,156 1,300 = 5.3 76 
Purification of rat Sertoli cell inhibin 
Batches of approximately 13 mg of Amicon 
concentrated rSCCM protein were chromato- 
graphed on Mono Q anion exchange columns. 
Inhibin bioactivity eluted between 140 and 260 
mmol/l NaCl (fraction 8-13, Fig. 2). The re- 
covery of applied inhibin bioactivity in the pooled 
bioactive fractions from the Mono Q columns was 
61% and 40% for the first and the second pool of 
rSCCM, respectively. We also used Lentil Lectin- 
Sepharose chromatography of Amicon con- 
centrated rSCCM. From this column 94 + 7.6% 
(mean f SEM, n = 5) of the recovered bioactivity 
could be eluted with 0.2 M a-methylmannoside, 
with no apparent increase in RSA. 
For method I, pooled bioactive fractions from 
the Mono Q columns with an RSA of 88.2 were 
separated in five runs on a Cl/C8 column, using 
a gradient of acetonitrile containing 0.1% TFA. 
Inhibin bioactivity was found in fractions 5, 6 and 
7 with an RSA of 425. However, after lyophiliza- 
tion RSA dropped to 121, indicating a 72% loss of 
bioactivity during this procedure. This material 
(1.56 mg) was separated by SDS-PAGE, eluted, 
methanol precipitated and analyzed for inhibin 
5 10 15 20 25 30 
fractm number 
Fig. 2. Anion-exchange chromatography of concentrated 
rSCCM on a Mono Q column. Proteins (- 1 GD,,,,) 
were eluted with a lineair gradient of O-600 mmol/l NaCl 
(- - -) in a 20 mmol/I Tris-HCl buffer pH 9.2. The hatched 
area represents inhibin bioactivity. 
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bioactivity. In eluates of slices 18 and 19, contain- 
ing proteins of 29-33 kDa, 65% of the applied 
bioactivity was recovered. On basis of amino acid 
sequence analysis, 7.5 pg protein was present in 
these eluates, resulting in a 800-fold purified in- 
hibin preparation with an RSA of 16.4 X 106. 
For method 2, bioactive fractions from a second 
pool of rSCCM separated on Mono Q columns, 
were combined. Proteins of this pool were sep- 
arated on a Cl8 column in a phosphate buffer at 
pH 6.8. Inhibin bioactivity was found in fractions 
25-40, with a recovery of 25% of the applied 
bioactivity (Fig. 3). Fractions 29-40, containing 
the peak of inhibin activity, were pooled, partly 
lyophilized and subsequently loaded onto an RP- 
300 Cl8 column. Proteins were eluted with a 
gradient of acetonitrile containing 0.1% TFA. All 
eluted inhibin bioactivity was found in fraction 18 
(Fig. 4) although most of the activity was lost (5% 
recovery). This eluate was used for amino acid 
sequencing. 
One-third of the Mono Q pool was purified in 
parallel. Inhibin bioactivity was again found in 
fraction 18 from the Cl8 column developed with 
the TFA buffer. The RSA of this inhibin prepara- 
tion was 1.3 x 103. This indicates a 76-fold purifi- 
Fig. 3. Reversed-phase chromatography of the inhibin contain- 
ing fractions from the Mono Q column (Fig. 2) on a Cl8 
column. Proteins (- , OJ’214nm) were duted with a lineair 
gradient of acetonitrile (- - -) in a phosphate buffer (10 
mrnol/l; pH 6.8). The hatched area represents inhibin bioactiv- 
ity. 
10 15 x1 hacbo” ““rnbm 
Fig. 4. Reversed-phase chromatography of the inhibin contain- 
ing fractions (29-40) from the Cl8 column in Fig. 3 on a Cl8 
column developed with a gradient of acetonitrile (- - -) in 
a buffer containing 0.1% TFA. Proteins (- 1 ODmnnJ 
and inhibin bioactivity (hatched area) are indicated. 
cation factor compared with rSCCM, with a yield 
of 0.035%. This preparation was also used for 
amino acid sequencing. 
Analysis of purified inhibin 
SDS-PAGE. Fractions of the latter column 
were analyzed by SDS-PAGE. Part of the gel was 
silver stained, whereas another part was used for 
Western blot analysis using an antibody against 
the 22 N-terminal amino acids of the a-subunit of 
32 kDa bovine inhibin. The appearance of im- 
munoreactive inhibin a-subunit (Fig. 5) coincided 
with the presence of bioactive inhibin in fraction 
18. Under non-reducing conditions a 32.5 kDa 
immunoreactive band was found. After reduction 
the apparent size of the immunoreactive protein 
was 19 kDa. The same bioactive fraction was also 
analyzed (with or without prior reduction) on 
Western blots with an antibody raised against the 
N-terminal amino acids 5-24 of the /3-A subunit 
of 32 kDa bovine inhibin. No immunoreactive 
bands were detected, although with bFF a 14 kDa 
band emerged after reduction (results not shown). 
Furthermore, no staining was observed when the 
blots were incubated with preimmune serum (data 
not shown). Silver staining of these samples re- 
vealed that in the bioactive fraction besides a 31.7 
kDa band two bands of 49 kDa en 21 kDa were 
present. After reduction of these samples the 31.7 
kDa band disappeared and 18.4 kDa and 11.7 
kDa bands emerged. Isoelectrofocussing and silver 
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staining of this sample revealed after silver stain- 
ing one prominent protein with an apparent iso- 
electric point of 4.8 (results not shown). 
Amino acid analysis. Purified fractions ob- 
tained after both methods 1 and 2 were subjected 
to N-terminal amino acid sequence analysis 
without further derivation. Most of the cycles 
revealed 2-4 amino acids. Table 2 lists the com- 
mon amino acids which were found in the inhibin 
preparations obtained after both purification 
methods and the amino acids as predicted from 
rat cDNA sequences (Esch et al., 1987; Woodruff 
et al., 1987). In all cycles, with the exception of 
cycle 9, the amino acids found were consistent 
with the presence of an (yP-B inhibin dimer in 
rSCCM, while the amino acids specific for the /?-A 
sequence were not detected. Glycine could not be 
detected with both methods in cycle 1 and 6, due 
western blot silver stain 
32.5 - 
- + - + 
Fig. 5. Western blot analysis with an antiserum agamst the 22 
N-terminal amino acids of the bovine inhibin a-subunit and 
silver staining of fraction 18 of Fig. 4. Fractions were analyzed 
by SDS-PAGE on 15% gels, with (+) or without (-) prior 
reduction with j3-mercaptoethanol. Indicated molecular weights 
are based on the positions of molecular weight markers, which 
have not been indicated in this figure. 
TABLE 2 
AMINO ACID SEQUENCE ANALYSIS OF INHIBIN 
PREPARATIONS PURIFIED ACCORDING TO TWO 
METHODS 
The N-terminal amino acid sequence of rat 30 kDa inhibin, 
derived from cDNA sequences (Esch et al., 1987 and Woodruff 
et al., 1987), is also presented for comparison. 
Cycle Amino acids Predicted amino 
detected with acids 
method 1 and 2 a 8-A 8-B 
1 S S G G 
2 QT.% L A L L 
3 P, E P E E 
4 S S C C 
5 D, M M D D 
6 P P G G 
7 W, R W K R 
8 P, T P V T 
9 K, L W N S 
10 S, L S I L 
11 P P C C 
12 A A C C 
13 A A K 
14 L, Q L K : 
15 R> Q R Q Q 
16 L L F F 
17 F, L L F F 
18 Q Q V I 
to residual glycine from the SDS-PAGE buffer. 
Cysteines were not identified in cycle 4, 11 and 12 
because no prior derivation was performed. 
Discussion 
Although rSCCM is a rich source of inhibin, 
with an RSA of 17-21 compared with bFF, it is 
difficult to obtain sufficient material for purifica- 
tion procedures. This was the reason to use the 
double collagenase method for the isolation of 
Sertoli cells, instead of the isolation method used 
to obtain highly purified Sertoli cells, which gives 
lower yields (Toebosch et al., 1989). Although in 
this rSCCM some peritubular cell derived proteins 
will be present, the report that the peritubular cell 
derived factor PmodS stimulates inhibin produc- 
tion (Skinner et al., 1989), makes it also attractive 
to use the former method. Up to the fifth week of 
culture appreciable amounts of bioactive inhibin 
were produced after an initial rise in the second 
week. 
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The Amicon hollowfibre concentration system 
with a molecular weight cut-off at 10 kDa was a 
convenient way to concentrate/exchange large 
pools of rSCCM in a short period. Inhibin bioac- 
tivity was never detected in the < 10 kDa frac- 
tions, also not after concentration of this fraction 
using a membrane with a cut-off at 1 kDa and 
testing equivalents up to 6 ml l-10 kDa rSCCM 
per 0.5 ml pituitary culture medium (data not 
shown). After concentration several purification 
steps have been explored. The Mono Q anion- 
exchange column resulted in inhibin preparations 
with high yields and a reasonable increase of RSA. 
When reversed-phase chromatography was per- 
formed directly on Amicon concentrated rSCCM, 
FSH-releasing activity eluting in front of inhibin 
was observed. After the Mono Q column this 
FSH-releasing activity was lost (results not shown). 
In the first purification method after the Mono 
Q column a Cl/C8 column was used, followed by 
SDS-PAGE. Amino acid sequence analysis re- 
vealed a heterogeneous preparation. With the sec- 
ond purification method, two reversed-phase chro- 
matography steps at neutral and acid pH were 
used. With this method a low RSA was obtained 
compared with the result of the first method. 
Western blot analysis of the inhibin preparation 
purified with method 2 revealed that only 15 U of 
bioactive inhibin resulted in a signal which was 
stronger than 1000 U starting rSCCM. This in- 
dicates that bioactivity is less stable than im- 
munoactivity, resulting in an underestimation of 
the RSA of the purified inhibin using method 2. 
A 32 kDa protein with inhibin bioactivity was 
purified from rSCCM. This protein is composed 
of a 18.4 kDa a-subunit and 11.7 kDa P-B sub- 
unit linked by disulphide bond(s). The molecular 
weight of this purified inhibin preparation con- 
firms the observation that in rat testis ho- 
mogenates and rSCCM directly separated by 
SDS-PAGE only one form of 32 kDa bioactive 
inhibin was found (Grootenhuis et al., 1989). This 
makes it likely that the 32 kDa cup-B inhibin 
molecule is the predominant form of inhibin in 
the rat testis, although it cannot be excluded com- 
pletely that other forms of inhibin have been lost 
during the purification procedure. Also Bicsak et 
al. (1987) reported a 30 kDa inhibin form in 
rSCCM chromatographed under denaturing con- 
ditions on a Superose-12 gel permeation column. 
A similar molecular weight form of inhibin (32 
kDa) was found in the conditioned medium of rat 
granulosa cells (Bicsak et al., 1986). Molecular 
weight estimations of rat testicular preparations 
using gel permeation chromatography under non- 
denaturing conditions revealed large differences 
(30-100 kDa) in molecular weight (Au et al., 
1983; Noguchi et al., 1987; Sharpe et al., 1988) 
probably due to hydrophobic interactions. The 
high molecular weight form of inhibin, found after 
Lentil Lectin-Sepharose chromatography of puri- 
fied rSCCM, which we reported earlier (de Jong et 
al., 1987) was probably due to a silver stain 
artefact at 65 kDa. 
The molecular weight of inhibin and its sub- 
units after reduction agrees well with the reports 
on purified 32 kDa ovarian inhibin (Ling et al., 
1985; Miyamoto et al., 1985; Rivier et al., 1985; 
Fukuda et al., 1986; Robertson et al., 1986; 
Leverha et al., 1987). The amino acid sequence 
which was obtained after combination of the data 
for the two inhibin preparations shows that rat 
Sertoli cell inhibin is an ap-B dimer. Additional 
evidence was obtained using an antiserum recog- 
nizing the /3-A subunit of inhibin; using this anti- 
serum no immunoreactive bands were detected on 
the Western blot. This agrees with the presence of 
mRNAs for the (Y- and 8-B subunits of inhibin in 
rat Sertoli cells and the low or undetectable levels 
of P-A mRNA (Toebosch et al., 1988; Feng et al., 
1989; Klaij et al., 1990). The only other reports on 
the characterization of male inhibin revealed a 30 
kDa (UP-A dimer in ovine testicular lymph (Bardin 
et al., 1987; Vaughan et al., 1989). 
The retention of inhibin bioactivity on Lentil 
Lectin-Sepharose indicates that rat inhibin is a 
glycoprotein as was reported for inhibin from 
other species. The isoelectric point of 32 kDa rat 
inhibin is similar to that reported by van Dijk et 
al. (1985) for bFF inhibin purified on a chro- 
matofocussing column. 
It is concluded that rat testicular inhibin is a 32 
kDa a/3-B dimer. This contrasts sharply with the 
situation in follicular fluid where both a&A and 
a/3-B dimers were found with a number of molecu- 
lar weight forms of inhibin (Ling et al., 1985; 
Robertson et al., 1985; Miyamoto et al., 1986; 
Grootenhuis et al., 1989). 
116 
Acknowledgements 
This work was supported in part by the Dutch 
Foundation for Medical Research (Medigon). We 
are grateful to the NIADDK, Bethesda, MD, 
U.S.A. for the supply of FSH and LH used in the 
radioimmunoassays. Amino acid sequences were 
determined at the Gas Phase Sequenator Facility 
(Department of Medical Biochemistry, State Uni- 
versity, Leiden, The Netherlands) which is sup- 
ported by the Dutch Foundation for the Advance- 
ment of Pure Research (NWO) through The 
Netherlands Foundation for Chemical Research 
(SON). 
References 
Au, C.L., Robertson, D.M. and de Kretser, D.M. (1983) Endo- 
crinology 112, 239-244. 
Bakker, G.H., Hoogerbrugge, J.W., Rommerts, F.F.G. and van 
der Molen, H.J. (1981) B&hem. J. 198, 339-346. 
Bardin, C.W., Morris, P.L., Chen, C.-L., Shaha, C., Voglmayr, 
J., Rivier, J., Spiess, J. and Vale W.W. (1987) in Inhibin- 
Non-Steroidal Regulation of Follicle Stimulating Hormone 
Secretion (Burger, H.G., Findlay, J.K., de Kretser, D.M. 
and Igarashi, M., eds.), pp. 179-190, Raven Press, New 
York. 
Bicsak, T.A., Tucker, E.M., Cappel, S., Vaughan, J., Rivier, J., 
Vale, W. and Hsueh, A.J.W. (1986) Endocrinology 119, 
2711-2719. 
Bicsak, T.A., Vale, W., Vaughan, J., Tucker, E.M., Cappel, S. 
and Hsueh, A.J.W (1987) Mol. Cell. Endocrinol. 49, 
211-217. 
Burger, H.G. and Igarashi, M. (1988) Acta Endocrinol. 118, 
159-160. 
Esch, F.S., Shimasaki, S., Cooksey, K., Mercado, M., Mason, 
A.J., Ying, S.-Y., Ueno, N. and Ling, N. (1987) Mol. 
Endocrinol. 1, 388-396. 
Feng, Z.-M., Bardin, C.W. and Chen, C.-L.C. (1989) Mol. 
Endocrinol. 3,939-948. 
Finney, D.J. (1964) in Statistical Methods in Biological Assay, 
2nd edn., pp. 101-138, Griffin, London. 
Fukuda, M., Miyamoto, K., Hasegawa, Y., Nomura, M., 
Igarashi, M., Kangawa, K. and Matsuo, H. (1986) Mol. 
Cell. Endocrinol. 44, 55-60. 
Grootenhuis, A.J., Steenbergen, J., Timmerman, M.A., Dors- 
man, A.N.R.D., Schaaper, W.M.M., Meloen, R.H. and de 
Jong, F.H. (1989) J. Endocrinol. 122, 293-301. 
de Jong, F.H. (1988) Physiol. Rev. 68, 555-607. 
de Jong, F.H. and Sharpe, R.M. (1976) Nature 263, 71-72. 
de Jong, F.H., Grootenhuis, A.J., Sander, H.J., Steenbergen, J., 
Timmerman, M.A. and van Dijk, S. (1987) in Inhibin- 
Non-Steroidal Regulation of Follicle Stimulating Hormone 
Secretion (Burger, H.G., Findlay, J.K., de Kretser, D.M. 
and Igarashi, M., eds.), pp. 35-46, Raven Press, New York. 
de Kretser, D.M. and Robertson, D.M. (1989) Biol. Reprod. 
40, 33-47. 
Klaij, I.A., Toebosch, A.M.W., Themmen, A.P.N., Shimasaki, 
S., de Jong, F.H. and Grootegoed, J.A. (1990) Mol. Cell. 
Endocrinol. 68,45-52. 
Laemmli, U.K. (1970) Nature 227, 680-685 
Leversha, L.J., Robertson, D.M., de Vos, F.L., Morgan, F.J., 
Heam, M.T.W., Wettenhall, R.E.H., Findlay, J.K., Burger, 
H.G. and de Kretser, D.M. (1987) J. Endocrinol. 113, 
213-221. 
Ling, N., Ying, S.-Y., Ueno, N., Esch, F., Denoroy, L. and 
Guillemin, R. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 
7217-7221. 
Miyamoto, K., Hasegawa, Y., Fukuda, M., Nomura, M., 
Igarashi, M., Kangawa, K. and Matsuo, H. (1985) B&hem. 
Biophys. Res. Commun. 129, 3966403. 
Miyamoto, K., Hasegawa, Y., Fukuda, M. and Igarashi, M. 
(1986) Biochem. Biophys. Res. Commun. 136, 1103-1109. 
Noguchi, K., Keeping, H.S., Winters, S.J., Saito, H., Oshima, 
H. and Troen, P. (1987) J. Clin. Endocrinol. Metab. 64, 
783-788. 
Oonk, R.B., Grootegoed, J.A. and van der Molen, H.J. (1985) 
Mol. Cell. Endocrinol. 42, 39-48. 
Rivier, J., Spiess, J., McClintock, R., Vaughan, J. and Vale, W. 
(1985) Biochem. Biophys. Res. Commun. 133, 120-127. 
Robertson, D.M., Foulds, L.M., Leversha, L., Morgan, F.J., 
Heam, M.T.W., Burger, H.G., Wettenhall, R.E.H. and de 
Kretser, D.M. (1985) B&hem. Biophys. Res. Commun. 
126, 220-226. 
Robertson, D.M., de Vos, F.L., Foulds, L.M., McLachlan, R.I., 
Burger, H.G., Morgan, F.J., Heam, M.T.W. and de Kretser, 
D.M. (1986) Mol. Cell. Endocrinol. 44, 271-277. 
Sharpe, R.M., Swanston, I.A., Cooper, I., Tsonis, C.G. and 
McNeilly, A.S. (1988) J. Endocrinol. 119, 315-326. 
Skinner, M.K., McLachlan, R.I. and Bremner, W.J. (1989) 
Mol. Cell. Endocrinol. 66, 239-249. 
Toebosch, A.M.W., Robertson, D.M., Trapman, J., Klaassen, 
P., de Paus, R.A., de Jong, F.H. and Grootegoed, J.A. 
(1988) Mol. Cell. Endocrinol. 55, 101-105. 
Toebosch, A.M.W., Robertson, D.M., Klaij, I.A., de Jong, F.H. 
and Grootegoed, J.A. (1989) J. Endoctinol. 122, 757-762. 
Vale, W., Rivier, C., Hsueh, A., Campen, C., Meunier, H., 
Bicsak, T., Vaughan, J., Corrigan, A., Bardin, W., 
Sawchenko, P., Petraglia, F., Yu, J., Plotsky, P., Spiess, J. 
and Rivier, J. (1988) Recent Prog. Hot-m. Res. 44, l-30. 
van Dijk, S., Steenbergen, C., de Jong, F.H. and van der 
Molen, H.J. (1985) Mol. Cell. Endocrinol. 42, 245-251. 
Vaughan, J.M., Rivier, J., Corrigan, A.Z., McClintock, R., 
Campen, C.A., Jolley, D., Voglmayr, J.K., Bardin, C.W., 
Rivier, C. and Vale, W. (1989) Methods Enzymol. 168, 
588-618. 
Waites, G.M.H., Bialy, G., Gordon, W.L., Findlay, J.K., de 
Jong, F.H., Robertson, D.M., Schwartz, N.B. and Stoning, 
P.L. (1987) in Inhibin-Non-Steroidal Regulation of Follicle 
Stimulating Hormone Secretion (Burger, H.G., Findlay, 
J.K., de Kretser, D.M. and Igarashi, M., eds.), pp. 281-287, 
Raven Press, New York. 
Woodruff, T.K., Meunier, H., Jones, P.B.C., Hsueh, A.J.W. 
and Mayo, K.E. (1987) Mol. Endocrinol. 1, 561-568. 
Wray, W., Boulikas, T., Wray, V.P. and Hancock, R. (1981) 
Anal. B&hem. 118, 197-203. 
